Licence represents inflection point which will drive growth in long term shareholder value
• Significant progress made towards finalising terms and conditions to secure Regeneus’ first clinical partner for Progenza in Japan
• Management anticipates the partnership to be secured and details of this collaboration will be announced this quarter
• This clinical collaboration will be an inflexion point for Regeneus, complementing the existing manufacturing relationship and commercial venture with AGC and positioning the company in Japan to grow long-term shareholder value
• Collaboration will provide a foundation for new collaborations in other key markets
RGS Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
